First Trimester

First-Trimester Maternal Changes and Symptoms

• Physiological Body Changes:

  • Cessation of menses (amenorrhea).

  • Breast enlargement and heightened tenderness.

  • Protrusion of the nipples.

  • Increased urinary frequency caused by hormonal shifts and uterine pressure.

• Common First-Trimester Symptoms:

  • Morning Sickness: Nausea and vomiting, commonly occurring early in the day but potentially lasting throughout the day.

  • Appetite and Digestive Alterations: Food cravings, severe food aversions, loss of appetite, heartburn, indigestion, abdominal bloating, excess gas, and constipation.

  • Systemic Symptoms: Severe fatigue, dizziness, and weight fluctuations (gaining or losing a few pounds initially).

• Symptom Management Guidelines:

  • Fatigue: Incorporate frequent rest periods throughout the day and ensure adequate sleep.

  • Breast Tenderness: Wear a supportive, well-fitting bra.

  • Urinary Frequency: Maintain hydration by focusing fluid intake during daylight hours, limiting fluids directly before bedtime to prevent sleep disruption.

  • Emotional Volatility: Acknowledge that rapid hormonal shifts cause an emotional roller coaster; ambivalence regarding pregnancy is common and expected during the first trimester.

  • Oral and Nasal Symptoms: Bleeding gums and epistaxis (nosebleeds) occur due to increased vascularity.

  • Leukorrhea: Increased odorless cervical mucus produces thin, white vaginal discharge; maintain hygiene using mild soap.

Prenatal Care Schedule and Clinical Assessments

• First Prenatal Visit:

  • Consultation: Meet with a Certified Nurse-Midwife (CNM) or Obstetrician (MD) to establish care and confirm the Estimated Date of Delivery (EDD).

  • Psychosocial & Safety Screening: Administration of the Edinburgh Postnatal Depression Scale, evaluation of lifestyle variables, and domestic safety assessment.

  • Diagnostic Blood Work: Serum pregnancy test, Complete Blood Count (CBC), Blood type and Rh factor determination, Rubella IgG titer, Varicella IgG titer, HIV screening, Hepatitis B surface antigen (HBsAg), and VDRL (syphilis screening).

  • Urinalysis & Clinical Baseline: Baseline blood pressure recording, urinalysis, optional genetic screening, and optional diagnostic ultrasound.

  • Nutritional Baseline: Calculation of Body Mass Index (BMI) and determination of weight gain goals. Initial weight loss may occur from morning sickness; target weight gain during the first trimester is $3\text{--}4\,\text{lbs}$.

• Second Prenatal Visit:

  • Comprehensive review of all baseline laboratory results.

  • Detailed medical and obstetrical history review.

  • Complete physical exam, including a pelvic examination, Pap smear, and endocervical cultures for Gonorrhea (GC) and Chlamydia.

• Routine Evaluations at Every Prenatal Visit:

  • Gestational age-pertinent topic discussions, delivery planning, and birth preparation.

  • Maternal weight check and blood pressure monitoring.

  • Fetal Heart Rate (FHR) check (audible via Doppler ultrasound after $9\,\text{weeks}$ gestation).

  • Abdominal Palpation & Measurement:

    • Palpation of the top of the uterus (fundus) above the symphysis pubis begins at approximately $12\,\text{weeks}$ gestation.

    • Fundal height measurement and abdominal palpation assess fetal presentation and growth velocity later in pregnancy.

• Fundal Height Milestones Throughout Gestation:

  • $12\,\text{Weeks}$: Fundus is palpable just above the pubic bone (symphysis pubis).

  • $14\text{--}16\,\text{Weeks}$: Fundus reaches midway between the symphysis pubis and the umbilicus.

  • $20\,\text{Weeks}$: Fundus reaches the level of the umbilicus.

  • $24\text{--}26\,\text{Weeks}$: Fundus continues rising above the umbilicus.

  • $32\,\text{Weeks}$: Fundus occupies the upper abdomen.

  • $36\text{--}38\,\text{Weeks}$: Fundus reaches its highest point, directly under the sternum (xiphoid process).

  • $40\,\text{Weeks}$ (Term): Fundal height drops below the $38\text{--}\text{week}$ level due to "lightening" as the fetal presenting part descends into the maternal pelvis.

Maternal Nutritional Requirements

• Caloric Targets by Trimester:

  • First Trimester: $1800\,\text{kcal/day}$.

  • Second Trimester: $2200\,\text{kcal/day}$.

  • Third Trimester: $2400\,\text{kcal/day}$.

• Hydration Requirements:

  • $8\text{--}12\,\text{cups/day}$ ($64\text{--}96\,\text{oz/day}$) of fluid.

• Essential Nutrients, Dietary Sources, and Maternal-Fetal Benefits:

  • Folic Acid: Sourced from leafy green vegetables, legumes, and fortified cereals/grains/pasta/rice. Prevents neural tube defects in the developing baby and builds embryonic cells.

  • Iron: Sourced from lean meats, spinach, beans, and fortified cereals. Supports expanded maternal blood volume and prevents gestational anemia.

  • Calcium: Sourced from dairy products, fortified plant-based milks, and leafy greens. Constructs strong fetal bones and teeth while preserving maternal bone density.

  • Protein: Sourced from lean meats, eggs, dairy, and legumes. Essential for the growth of fetal tissues and placental development.

  • Omega-3 Fatty Acids: Sourced from fatty fish, flaxseeds, and walnuts. Crucial for fetal brain, nerve, and ocular development.

  • Vitamin D: Sourced from fortified dairy, fatty fish, and direct sunlight exposure. Supports bone growth and immune function.

  • Vitamin C: Sourced from citrus fruits, berries, and bell peppers. Enhances non-heme iron absorption and strengthens immune function.

  • Fiber: Sourced from whole grains, fruits, and vegetables. Aids gastrointestinal digestion and prevents constipation.

  • Iodine: Essential for healthy fetal brain development.

  • Prenatal Vitamins: A daily prenatal vitamin supplement is indicated to fill dietary nutritional gaps.

Neural Tube Defects and Folic Acid Supplementation

• Biological Importance of Folate:

  • Drives fetal cell synthesis and neurological development.

  • Essential for proper closure of the neural tube, which forms the brain, skull, spinal cord, and spine.

  • Neural tube closure occurs rapidly between $21\,\text{days}$ and $28\,\text{days}$ post-conception.

• Dosing Recommendations:

  • Supplemental Dose: $400\,\mu\text{g/day}$ as a standalone supplement.

  • Total Daily Requirement: $600\text{--}800\,\mu\text{g/day}$.

  • Prenatal Vitamin Content: Standard prenatal vitamins supply $400\text{--}800\,\mu\text{g}$.

  • Critical Window: Supplementation is most crucial preconception and throughout the first trimester.

• Neural Tube Defects (NTDs):

  • Spina Bifida Occulta: A mild, hidden vertebral defect where the bone fails to close around the spinal cord, often marked externally by a sacral hair tuft.

  • Meningocele: A fluid-filled sac containing meninges and cerebrospinal fluid protruding through a vertebral cleft, without involving spinal nerves.

  • Myelomeningocele: The most severe form of spina bifida, where both the meninges and the spinal cord/nerves herniate into an external sac, leading to neurological impairment.

  • Anencephaly: Cephalic neural tube failure resulting in the congenital absence of major portions of the brain, skull, and scalp; infants are born with only a brain stem and cannot survive.

Hematologic and Infectious Disease Screening

• Gestational Anemia:

  • Diagnostic Thresholds (1st Trimester): Hemoglobin $\text{Hgb} < 11\,\text{g/dL}$ or Hematocrit $\text{Hct} < 33\%$.

  • Risk Factors: Closely spaced pregnancies, multifetal pregnancy, hyperemesis/severe morning sickness (loss of nutrients via emesis), rapid expansion of maternal blood volume, inadequate dietary iron intake, or pre-existing iron deficiency.

  • Therapeutic Management:

    • Oral iron supplementation as prescribed (Ferrous Sulfate QD [once daily] or BID [twice daily]).

    • Take iron supplements between meals with orange juice (Vitamin C) to optimize intestinal absorption.

    • Avoid taking iron supplements alongside coffee, tea, chocolate, or high-fiber foods; these contain polyphenols and phytates that hinder iron absorption.

    • Consume dietary iron: Lean meats, fish, dark green leafy vegetables, legumes, dried fruits, whole grains, and peanut butter.

    • Mitigate iron-induced constipation through exercise, increased fluid intake, and high-fiber foods.

• Rubella (German Measles):

  • Serology: A positive Rubella IgG titer indicates maternal immunity.

  • Maternal Symptoms: Mild flu-like illness characterized by low-grade fever, headache, mild conjunctivitis, generalized discomfort, retroauricular/cervical lymphadenopathy, cough, and coryza.

  • Fetal Risk: High transmission rate ($85\%$) during early pregnancy. Causes fetal demise or Congenital Rubella Syndrome (cardiac defects, microphthalmia/cataracts, and sensorineural deafness).

  • Vaccination Protocol: Rubella vaccine is a live attenuated virus and is strictly CONTRAINDICATED during pregnancy due to theoretical risks of placental transmission. Non-immune mothers are vaccinated postpartum prior to discharge.

• Varicella (Chickenpox):

  • Serology: Positive IgG indicates immunity; non-immune mothers require postpartum vaccination with live attenuated varicella vaccine.

  • Maternal Symptoms: Itchy, vesicopustular rash that crusts over, accompanied by fever, headache, fatigue, and anorexia. Treated supportively with antivirals, oatmeal baths, and calamine lotion.

  • Fetal Risk: A $2\%$ risk of Congenital Varicella Syndrome, causing fetal limb hypoplasia, ocular defects, cutaneous scarring, microcephaly, and severe developmental delays.

  • Post-Exposure Intervention: Non-immune pregnant women exposed to Varicella must receive Varicella Zoster Immunoglobulin (VZIG) within $10\,\text{days}$ of exposure to confer passive immunity.

• Urinalysis and Urine Culture:

  • A full laboratory urinalysis is performed at the initial visit (rather than a simple dipstick).

  • Screening Parameters: hCG (confirms pregnancy), RBCs, WBCs, bacteria, yeast, parasites, and nitrites (produced by pathogenic urinary bacteria).

  • Pathological Markers:

    • Protein: Elevated levels indicate renal disease or early preeclampsia.

    • Glucose: Elevated levels indicate diabetes mellitus.

    • Ketones: Elevated levels signal dehydration or inadequate caloric intake.

    • Specific Gravity: Normal reference range is $1.005\text{--}1.030$; elevated specific gravity reflects concentrated urine from maternal dehydration.

• Sexually Transmitted Infection (STI) Screening Schedule:

  • First Prenatal Visit: VDRL (Syphilis), HBsAg (Hepatitis B Surface Antigen), and HIV screening.

  • Second Prenatal Visit: Endocervical cultures for Gonorrhea (GC) and Chlamydia; Pap smear with reflexive HPV testing for atypical cytology.

Blood Typing, Rh Incompatibility, and Isoimmunization

• ABO and Rh Blood Antigens:

  • Antigens: Surface markers on red blood cells capable of triggering an immune response.

  • Rh Factor: Refers specifically to the 'D' antigen.

  • Type AB Positive: Universal recipient; expresses A, B, and D antigens, thus generating no anti-A, anti-B, or anti-D antibodies.

  • Type O Negative: Universal donor; lacks A, B, and D antigens, preventing immune recognition upon transfusion into recipients.

• Rh Incompatibility Pathophysiology:

  • Exposure Mechanisms: Occurs when an Rh-negative mother is exposed to Rh-positive fetal red blood cells. Fetal-maternal hemorrhage occurs via placental micro-leaks during pregnancy, blood mixing during labor/delivery (placental separation), invasive procedures (amniocentesis, Chorionic Villus Sampling), spontaneous or induced miscarriage, ectopic pregnancy, or blunt abdominal trauma.

  • Sensitization Sequence: The initial Rh-positive pregnancy is typically unaffected. Fetal RBC entry into maternal circulation during delivery causes the mother to build sensitivity and produce anti-Rh (anti-D) IgG antibodies. In subsequent Rh-positive pregnancies, maternal anti-Rh IgG antibodies cross the placenta and destroy fetal red blood cells.

  • Erythroblastosis Fetalis (Hemolytic Disease of the Newborn): Severe intra-uterine hemolysis leading to fetal anemia, hepatosplenomegaly, jaundice, tissue hydrops, and potential fetal or neonatal death.

• RhoD Immune Globulin (RhoGAM) Protocol:

  • Mechanism: Intramuscular injection of passive RhoD antibodies that destroy circulating Rh-positive fetal red blood cells before the maternal immune system recognizes them, preventing active antibody synthesis.

  • Standard Dosing Schedule: Administered routinely at $28\,\text{weeks}$ gestation to all Rh-negative mothers. A second dose is administered within $72\,\text{hours}$ postpartum IF the infant's cord blood is confirmed Rh-positive.

  • Interim Indications: Administered following any event with potential fetal-maternal hemorrhage: amniocentesis, CVS, miscarriage, abdominal trauma, or placental abruption.

• Laboratory Tests for Hemolytic Risk:

  • Indirect Coombs Test: Performed on maternal serum during routine prenatal screening to detect circulating anti-D antibodies (determines if sensitization has already occurred).

  • Direct Coombs Test (DAT): Performed on umbilical cord or neonatal RBCs to detect attached anti-D maternal antibodies. A positive DAT indicates active hemolysis and impending neonatal jaundice.

  • Kleihauer-Betke (KB) Test: A quantitative acid-elution assay performed on maternal blood. Maternal adult hemoglobin ($\text{HbA}$) dissolves under acid treatment, whereas fetal hemoglobin ($\text{HbF}$) resists acid elution and retains a bright pink appearance. Quantifies the volume of fetal-maternal hemorrhage; if fetal blood volume in maternal circulation exceeds $15\,\text{mL}$, the mother requires more than one dose of RhoGAM postpartum.

First-Trimester Bleeding and Miscarriage

• Definition & Incidence: Spontaneous loss of a pregnancy prior to $20\,\text{weeks}$ gestation. Affects $10\text{--}20\%$ of clinically recognized pregnancies (overall rate is higher due to unrecognised early losses).

• Etiologies and Risk Factors: Chromosomal abnormalities (most common cause), maternal hormonal imbalances, endocrine disorders (uncontrolled diabetes mellitus, thyroid disease), acute or chronic infections, structural uterine abnormalities (fibroids, uterine scarring), and maternal physical trauma.

• Clinical Presentation of Miscarriages:

  • Vaginal bleeding ranging from light spotting to heavy flow.

  • Abdominal pain or pelvic cramping.

  • Passing of tissue, clots, or products of conception.

  • Sudden disappearance of systemic pregnancy symptoms (e.g., loss of morning sickness or breast tenderness).

• Diagnostic Classifications:

  • Threatened Miscarriage: Vaginal bleeding present, cervical os remains closed, fetal cardiac activity is documented on ultrasound.

  • Inevitable Miscarriage: Vaginal bleeding present, cervical os is dilated, products of conception are felt or visualized at or above the cervical os.

  • Incomplete Miscarriage: Vaginal bleeding present, cervical os is dilated, partial expulsion of products of conception (some tissue expelled, some retained in utero).

  • Complete Miscarriage: Vaginal bleeding present, cervical os closes after complete expulsion of all products of conception.

• Surgical Management:

  • Dilatation and Curettage (D&C): Indicated up to $13\,\text{weeks}$ gestation for heavy bleeding, tissue retention, or infection. Uses a curette or suction curettage ($20\text{-minute}$ procedure).

  • Dilatation and Evacuation (D&E): Indicated at $13+\,\text{weeks}$ gestation. Utilizes vacuum aspiration, forceps, and curettage ($30\text{-minute}$ procedure).

  • Surgical Risks: Uterine or bowel perforation (risk increases as gestational age advances), pelvic infection, severe hemorrhage, cervical trauma, and intra-uterine scar tissue formation.

• Post-Procedure Nursing & Discharge Instructions:

  • Confirm maternal blood type and administer RhoGAM within $72\,\text{hours}$ if Rh-negative.

  • Recovery Expectations: Irregular spotting or light bleeding for up to $2\,\text{weeks}$ postpartum; cramping lasting a few hours to several days (managed with heating pads and oral analgesics).

  • Complication Warnings (When to Call Provider): Maternal fever, worsening pelvic pain, or foul-smelling vaginal discharge.

Abnormal Implantations and Gestational Trophoblastic Disease

• Ectopic Pregnancy:

  • Definition & Incidence: Implantation of a fertilized egg outside the uterine endometrial cavity, most commonly within the fallopian tube. Represents approximately $2\%$ of all pregnancies.

  • Risk Factors: History of pelvic inflammatory disease (PID), previous ectopic pregnancy, structural tubal damage/scarring, assisted reproductive technology (IVF), and advanced maternal age ($> 35\,\text{years}$).

  • Clinical Presentation: Spotting/vaginal bleeding, localized lower abdominal pain, dizziness/syncope, nausea, and referred shoulder pain. Referred shoulder pain occurs because intra-abdominal blood irritates the diaphragm; the phrenic nerve originates from spinal segments $C3\text{--}C5$, sharing sensory pathways with the shoulder region.

• Medical Treatment (Methotrexate):

  • Folic acid antagonist that halts rapidly dividing trophoblastic cells, leading to pregnancy resorption over $4\text{--}6\,\text{weeks}$ without tubal removal.

  • Success rate is $> 95\%$ when administered before $8\,\text{weeks}$ gestation.

  • Dosed as a single intramuscular (IM) injection of $50\,\text{mg/m}^2$ (Note: administered weekly for ectopic pregnancy, whereas daily dosing is reserved for oncology regimens due to severe toxicity).

  • Strict Patient Warnings: Avoid folic acid supplements, abstain from sun/UV exposure (prevents severe phototoxic skin reactions), and abstain from sexual intercourse/vigorous physical activity to avoid tubal rupture.

• Surgical Treatment:

  • Laparoscopy: Salpingostomy (removal of the ectopic pregnancy with surgical repair of the tube) or Salpingectomy (resection of the affected fallopian tube).

  • Laparotomy: Lower abdominal incision required in cases of acute tubal rupture with severe internal hemorrhage.

• Blighted Ovum (Anembryonic Pregnancy):

  • An early form of miscarriage ($1\text{--}3\%$ of pregnancies) where a fertilized egg implants in the uterus but fails to develop an embryo.

  • Diagnosis: Confirmed via transvaginal ultrasound showing an empty gestational sac.

  • Management: Expectant management (awaiting natural expulsion), administration of Prostaglandin E2 gel to induce uterine contractions, or surgical D&C. Most patients go on to have successful future pregnancies.

• Molar Pregnancy (Hydatidiform Mole):

  • Pathophysiology: Abnormal proliferation of trophoblasts (cells surrounding the fertilized egg), forming mass clusters of fluid-filled cysts instead of a normal placenta/fetus.

  • Complete Hydatidiform Mole: Two sperm fertilize an empty egg (lacking maternal chromosomes). Results in a $46$-chromosome karyotype composed entirely of paternal DNA. No fetal tissue is present.

  • Partial Hydatidiform Mole: One normal egg is fertilized by two sperm (or one unreduced sperm). Results in a triploid $69$-chromosome karyotype. Some non-viable fetal tissue develops alongside cystic changes.

  • Incidence: $1/1000$ pregnancies in the USA; ranges up to $1/100$ to $2/1000$ in Asian populations.

  • Clinical Features: Dark red ("prune juice") or bright red vaginal bleeding, severe hyperemesis gravidarum, pelvic pressure/pain, expulsion of grape-like vesicles per vaginam, and uterine enlargement disproportionately rapid for gestational age.

  • Diagnostic Findings:

    • Ultrasound: Demonstrates a classic "snowstorm" pattern produced by hydropic villi interspersed within an echogenic mass.

    • Laboratory: Abnormally high, soaring $\beta\text{-hCG}$ levels compared to a physiological pregnancy (e.g., reaching $69,728.36\,\text{mIU/mL}$ at $11\text{--}12\,\text{weeks}$ versus $5,387.36\,\text{mIU/mL}$ in normal pregnancy).

• Therapeutic Management & Oncologic Follow-Up:

  • Surgical evacuation via suction D&C or hysterectomy; histopathological verification is mandatory.

  • Malignancy Risk: Incomplete tissue removal can trigger Gestational Trophoblastic Neoplasia (GTN) or Choriocarcinoma ($5\%$ of complete moles progress to choriocarcinoma).

  • Surveillance Protocol: Monitor serial quantitative $\beta\text{-hCG}$ levels for $6\,\text{months}$ (complete mole) or every $2\,\text{weeks}$ until undetectable, followed by monthly testing for $4\,\text{weeks}$ (partial mole).

  • Contraception Requirement: The patient must strictly avoid pregnancy for $6\,\text{months}$ to $1\,\text{year}$, as rising physiological hCG levels prevent accurate detection of malignant GTN recurrence.

Severe Gestational Nausea and Hyperemesis Gravidarum

• Definition & Incidence: A severe, intractable form of gestational nausea and vomiting affecting $0.3\text{--}3\%$ of pregnancies, far exceeding standard morning sickness.

• Clinical Manifestations & Diagnostics:

  • Persistent, uncontrollable emesis leading to systemic dehydration.

  • Weight loss exceeding $5\%$ of pre-pregnancy body weight.

  • Presence of ketonuria (indicating fat catabolism) and serum electrolyte imbalances.

  • Sialorrhea (excessive salivation), constipation, severe fatigue, dizziness, and postural hypotension.

• Therapeutic Interventions:

  • Inpatient Hospitalization Criteria: Indicated for persistent emesis despite oral antiemetics, intractable ketonuria, weight loss $> 5\%$, or co-existing infections (e.g., UTI with inability to retain oral antibiotics). Maintained NPO initially with intravenous fluid/electrolyte rehydration.

  • First-Line Pharmacotherapy: Vitamin B6 (pyridoxine) combined with Doxylamine (an over-the-counter sleep aid); this combination reduces nausea and vomiting by up to $70\%$.

  • Second-Line Pharmacotherapy: Ondansetron (Zofran), utilized if first-line therapy fails.

  • Refractory Option: Metoclopramide (Reglan), recommended as a last-resort intervention by ACOG guidelines.

• Nursing Care Protocols: Daily body weight measurements, strict Intake and Output (I&O) recording, vital signs assessment, and continuous monitoring for signs of dehydration (skin turgor, dry mucous membranes).

First-Trimester Diagnostic Procedures: Chorionic Villus Sampling (CVS)

• Procedure Overview: A prenatal diagnostic procedure involving the biopsy of placental chorionic villi to perform fetal karyotyping and detect early chromosomal/genetic abnormalities.

• Gestational Window: Performed between $10\,\text{weeks}$ and $12\,\text{weeks}$ gestation.

  • Contraindication: Performing CVS prior to $9\,\text{weeks}$ gestation causes severe fetal transverse limb reduction defects.

  • Spontaneous Abortion Risk: Approximately $1/100$ ($1\%$).

• Procedural Approaches:

  • Transabdominal Approach: Continuous ultrasound guidance directs an abdominal needle through the maternal abdominal wall into the placental mass to aspirate villi.

  • Transcervical Approach: Speculum insertion allows a sterile, flexible catheter to pass through the cervical canal into the placenta under continuous ultrasound visualization.

• Indications & Procedural Complications:

  • Indications: Confirms genetic anomalies early, allowing for safer, less complex first-trimester pregnancy termination if chosen.

  • Complications: Spontaneous abortion, fetal limb reduction defects (if done $< 9\,\text{weeks}$), intra-amniotic infection, and premature rupture of membranes (PROM).

• Nursing Interventions and Discharge Protocol:

  • Obtain informed consent, administer RhoGAM post-procedure to Rh-negative mothers, and ensure a full maternal bladder prior to the transabdominal procedure to elevate the uterus.

  • Post-Procedure Restrictions (First $72\,\text{Hours}$ / $3\,\text{Days}$):

    • No vigorous activities or physical exercise.

    • No tampon usage (use pads exclusively if spotting occurs).

    • No sexual intercourse.

    • No heavy lifting exceeding $20\,\text{lbs}$.

    • No tub baths or swimming.

    • Postpone long-distance travel for $5\text{--}7\,\text{days}$.

  • Urgent Medical Red Flags: Immediate call required for gushing fluid/water loss, heavy bleeding (exceeding normal menses), maternal fever $> 100.4^\circ\text{F}$ or chills, severe abdominal cramps, or foul-smelling discharge.